FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2000443242> ?p ?o ?g. }

• W2000443242 endingPage "2161" @default.
• W2000443242 startingPage "2161" @default.
• W2000443242 abstract "Within the past 10 years, several immunomodulatory agents (IMAs) have become available for the treatment of relapsing multiple sclerosis (MS), making therapeutic decisions more complex. We performed a systematic review of the literature to assess the efficacy and safety of these agents on physical, inflammatory, and cognitive measures of disease activity.We identified relevant studies by searching electronic databases (MEDLINE and Current Contents) from January 1, 1993, through August 31, 2001. We included English-language reports of data from phase 3 trials of interferon beta-1b (Betaseron), 2 preparations of interferon beta-1a (Avonex and Rebif), or glatiramer acetate (Copaxone) for the treatment of relapsing MS.Twenty-one studies met explicit inclusion criteria. Comparison of study results indicated no differences among IMAs regarding their efficacy on relapse-related measures. Interferon beta-1a significantly reduced disability progression, whereas no significant effect of glatiramer acetate or interferon beta-1b on disability progression was seen. On inflammatory measures, all of the IMAs showed reductions in the burden of disease (T2-weighted lesions) to varying degrees. Interferon beta and glatiramer acetate reduced new lesion activity; however, interferon beta had a more profound effect. One interferon beta-1a preparation (Avonex) appeared to reduce brain atrophy, whereas glatiramer acetate showed an effect in 1 of 2 studies. Only Avonex demonstrated efficacy in slowing progression of cognitive dysfunction.Data show that the IMAs have similar effects on several physical and inflammatory measures. In addition, Avonex has demonstrated efficacy in slowing cognitive progression in relapsing MS. One disadvantage of interferon beta is the possibility of immunogenicity, which may occur more often with subcutaneous administration. The IMAs have similar safety and tolerability profiles." @default.
• W2000443242 created "2016-06-24" @default.
• W2000443242 creator A5000976216 @default.
• W2000443242 creator A5031416421 @default.
• W2000443242 creator A5081144092 @default.
• W2000443242 date "2002-10-28" @default.
• W2000443242 modified "2023-10-16" @default.
• W2000443242 title "Immunomodulatory Agents for the Treatment of Relapsing Multiple Sclerosis" @default.
• W2000443242 cites W1975104912 @default.
• W2000443242 cites W1994748256 @default.
• W2000443242 cites W1998455368 @default.
• W2000443242 cites W2005506388 @default.
• W2000443242 cites W2008627981 @default.
• W2000443242 cites W2015052590 @default.
• W2000443242 cites W2015238396 @default.
• W2000443242 cites W2017449946 @default.
• W2000443242 cites W2023180387 @default.
• W2000443242 cites W2023385152 @default.
• W2000443242 cites W2036284753 @default.
• W2000443242 cites W2053465447 @default.
• W2000443242 cites W2053867270 @default.
• W2000443242 cites W2056174060 @default.
• W2000443242 cites W2057005657 @default.
• W2000443242 cites W2060129459 @default.
• W2000443242 cites W2066433792 @default.
• W2000443242 cites W2087589796 @default.
• W2000443242 cites W2100650001 @default.
• W2000443242 cites W2100721517 @default.
• W2000443242 cites W2105477343 @default.
• W2000443242 cites W2110307088 @default.
• W2000443242 cites W2110386728 @default.
• W2000443242 cites W2112165124 @default.
• W2000443242 cites W2116064638 @default.
• W2000443242 cites W2124647006 @default.
• W2000443242 cites W2127086238 @default.
• W2000443242 cites W2132228594 @default.
• W2000443242 cites W2139367012 @default.
• W2000443242 cites W2142846397 @default.
• W2000443242 cites W2151529161 @default.
• W2000443242 cites W2164542304 @default.
• W2000443242 cites W2165547142 @default.
• W2000443242 cites W2169098250 @default.
• W2000443242 cites W2473645617 @default.
• W2000443242 cites W2485483395 @default.
• W2000443242 cites W2509277703 @default.
• W2000443242 cites W2513768836 @default.
• W2000443242 cites W1967733776 @default.
• W2000443242 doi "https://doi.org/10.1001/archinte.162.19.2161" @default.
• W2000443242 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12390057" @default.
• W2000443242 hasPublicationYear "2002" @default.
• W2000443242 type Work @default.
• W2000443242 sameAs 2000443242 @default.
• W2000443242 citedByCount "75" @default.
• W2000443242 countsByYear W20004432422012 @default.
• W2000443242 countsByYear W20004432422013 @default.
• W2000443242 countsByYear W20004432422014 @default.
• W2000443242 countsByYear W20004432422015 @default.
• W2000443242 countsByYear W20004432422020 @default.
• W2000443242 crossrefType "journal-article" @default.
• W2000443242 hasAuthorship W2000443242A5000976216 @default.
• W2000443242 hasAuthorship W2000443242A5031416421 @default.
• W2000443242 hasAuthorship W2000443242A5081144092 @default.
• W2000443242 hasBestOaLocation W20004432421 @default.
• W2000443242 hasConcept C126322002 @default.
• W2000443242 hasConcept C168563851 @default.
• W2000443242 hasConcept C1862650 @default.
• W2000443242 hasConcept C203014093 @default.
• W2000443242 hasConcept C2776178377 @default.
• W2000443242 hasConcept C2778577042 @default.
• W2000443242 hasConcept C2779134260 @default.
• W2000443242 hasConcept C2780640218 @default.
• W2000443242 hasConcept C2908698914 @default.
• W2000443242 hasConcept C2910198813 @default.
• W2000443242 hasConcept C2994247566 @default.
• W2000443242 hasConcept C535046627 @default.
• W2000443242 hasConcept C71924100 @default.
• W2000443242 hasConceptScore W2000443242C126322002 @default.
• W2000443242 hasConceptScore W2000443242C168563851 @default.
• W2000443242 hasConceptScore W2000443242C1862650 @default.
• W2000443242 hasConceptScore W2000443242C203014093 @default.
• W2000443242 hasConceptScore W2000443242C2776178377 @default.
• W2000443242 hasConceptScore W2000443242C2778577042 @default.
• W2000443242 hasConceptScore W2000443242C2779134260 @default.
• W2000443242 hasConceptScore W2000443242C2780640218 @default.
• W2000443242 hasConceptScore W2000443242C2908698914 @default.
• W2000443242 hasConceptScore W2000443242C2910198813 @default.
• W2000443242 hasConceptScore W2000443242C2994247566 @default.
• W2000443242 hasConceptScore W2000443242C535046627 @default.
• W2000443242 hasConceptScore W2000443242C71924100 @default.
• W2000443242 hasIssue "19" @default.
• W2000443242 hasLocation W20004432421 @default.
• W2000443242 hasLocation W20004432422 @default.
• W2000443242 hasOpenAccess W2000443242 @default.
• W2000443242 hasPrimaryLocation W20004432421 @default.
• W2000443242 hasRelatedWork W1983662281 @default.
• W2000443242 hasRelatedWork W2000443242 @default.
• W2000443242 hasRelatedWork W2406066426 @default.
• W2000443242 hasRelatedWork W2504156208 @default.

• next